Acute respiratory failure in COVID-19: is it "typical" ARDS?

Area of Science:

• Pulmonology
• Infectious Diseases
• Critical Care Medicine

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, presents a significant global health threat.
• Acute Respiratory Distress Syndrome (ARDS) is a severe complication of COVID-19, necessitating a deeper understanding of its unique characteristics.
• Distinguishing COVID-19 ARDS from ARDS of other etiologies is crucial for targeted therapeutic strategies.

Purpose of the Study:

• To delineate the specific clinical and pathological features of COVID-19-related ARDS.
• To compare and contrast COVID-19 ARDS with ARDS resulting from other causes.
• To propose a refined staging system for COVID-19 ARDS severity.

Main Methods:

• Retrospective analysis of clinical data from COVID-19 patients with ARDS.
• Comparison of pathological findings and clinical manifestations with historical ARDS cohorts.
• Evaluation of treatment responses, including High-Flow Nasal Oxygen (HFNO) and mechanical ventilation.

Main Results:

• COVID-19 ARDS predominantly affects the respiratory system, with alveolar epithelial injury being a key factor and less endothelial damage compared to other ARDS types.
• Clinical presentation in some patients was milder than suggested by imaging and laboratory findings, with a delayed onset (8-12 days) compared to Berlin criteria.
• A novel three-stage severity classification (mild, mild-moderate, moderate-severe) was proposed; HFNO demonstrated safety even in moderate-severe cases.

Conclusions:

• COVID-19 ARDS exhibits unique pathological and clinical characteristics, including potential for normal lung compliance in some cases and delayed onset.
• The proposed staging system may aid in more precise management of COVID-19 ARDS.
• Timely initiation of invasive mechanical ventilation is critical, while the role of corticosteroids remains uncertain; HFNO appears safe for a broader range of patients.